Logic Bio

LogicBio is developing its proprietary gene therapy platform in order to provide lifelong cures for serious, early-onset rare diseases by combining the best of gene therapy and gene editing. Its GeneRide™ technology enables nuclease-free and promoterless site-specific integration of a therapeutic gene into the genome, allowing durable gene expression in dividing cells.

biopharmaceuticals
Public (NASDAQ:LOGC)
Visit Website
Additional Portfolio Companies
Abcuro
Adicet Bio
AgomAb Therapeutics
Allena Pharmaceuticals
ArQule
Cathworks
cCAM Biotherapeutics
CheckCap
CytoReason
Dynacure
Eloxx Pharmaceuticals
Enlivex Therapeutics
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Genocea
Horama
IMEL Biotherapeutics
Immunic Therapeutics
Kamari Pharma
Keros Therapeutics
Kite Pharma
Levation Pharma
LogicBio Therapeutics
Lutris Pharma
Mereo BioPharma
Metabomed
NovellusDX
Ocon Medical
Opiant
PACT Pharma
Pi Therapeutics
Prevail Therapeutics
Precirix (Formerly Camel-IDS)
ProQR
Protalix
Raziel Therapeutics
ReWalk
Saniona
SilverBack Therapeutics
Soligenix
Stargazer Pharmaceuticals
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
Vascular Graft Solutions
UroGen
V-Wave
June 25, 2017